Sponsored by
The annual European Association of Neuro-Oncology conference (EANO 2024) is coming up in a few weeks, and one of the presentations will share data from the Phase 0/1 study of mycophenolate mofetil (MMF) in newly diagnosed and recurrent glioblastoma (GBM). MMF inhibits an enzyme required for purine metabolism in GBM cells. The study, although small, showed effective target engagement and inhibition of purine synthesis. Interim median overall survival was 15.6 in the recurrent GBM arm of the study and was not yet reached in the newly diagnosed arm. Based on the study results, the investigators have identified a recommended dose for a future Phase 2 trial.